On October 23, 2026, Roche secured exclusive global rights to Zymeworks' experimental lung cancer drug ZW209 in a licensing deal worth up to $813 million. Zymeworks receives $55 million upfront and $40 million at the start of a Phase 1b trial, alongside up to $718 million in development and commercial milestones plus tiered royalties. ZW209 is a trispecific T-cell engager targeting the DLL3 protein on small cell lung cancer cells. Zymeworks runs the initial Phase 1a study funded by Roche, after which Roche assumes all global development and commercialization.
Agreement overview and closing conditions
- ▪The licensing deal between Zymeworks and Roche for ZW209 is subject to customary closing conditions and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
- ▪Zymeworks entered into an exclusive global licensing agreement with Roche for its experimental lung cancer drug ZW209 in a deal worth up to $813 million on October 23, 2026.
Financial terms of the deal
- ▪Roche agreed to pay Zymeworks an upfront payment of $55 million for the global rights to ZW209.
- ▪Roche will pay Zymeworks an additional $40 million upon the initiation of a planned dose-optimization Phase 1b trial of ZW209.
- ▪Zymeworks is entitled to receive tiered high-single-digit to mid-teen royalties on future net sales of ZW209 under the Roche agreement.
- ▪Zymeworks is eligible to receive up to $718 million in additional development, regulatory, and commercial milestone payments from Roche for ZW209.
Division of development responsibilities
- ▪Roche will take over all subsequent global development, regulatory activities, and commercialization of ZW209 following Zymeworks' completion of the dose-escalation Phase 1a study.
- ▪Zymeworks will run the ongoing Phase 1a trial evaluating ZW209 monotherapy in collaboration with Roche, while Roche will fund the trial.
Clinical trial status and timeline
- ▪The U.S. Food and Drug Administration cleared an Investigational New Drug application for ZW209, allowing the initiation of Phase 1 clinical testing.
- ▪Zymeworks CEO Kenneth Galbraith stated that the first patient is expected to be enrolled in ZW209 clinical testing before the end of 2026.
Previous corporate partnership history
- ▪In April 2026, Bristol Myers Squibb terminated the final asset under its legacy collaboration alliance with Zymeworks and Celgene.
- ▪Zymeworks previously established royalty-bearing partnerships with Jazz Pharmaceuticals in 2022 for Ziihera and with Johnson & Johnson in 2017 for six bispecific antibodies.
ZW209 characteristics and Phase 1 trial
- ▪Phase 1 clinical testing of ZW209 was initiated to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity in adult participants with select advanced solid tumors.
- ▪ZW209 is a preclinical trispecific T-cell engager targeting DLL3, a protein expressed on small cell lung cancer and neuroendocrine tumor cells, while engaging T cells via CD3 and CD28.
Executive statements on ZW209 deal
- ▪Zymeworks Executive Vice President and Head of R&D Adam Schayowitz stated that the collaboration allows Zymeworks to advance ZW209 through initial clinical development while leveraging Roche's complementary capabilities.
- ▪Zymeworks CEO Kenneth Galbraith stated that Roche partnered on ZW209 before efficacy data was available due to the innovation and differentiation in Zymeworks' trispecific T-cell engager platform.
Leerink Partners assessment of Zymeworks
- ▪Leerink Partners noted that the Roche agreement validates Zymeworks' business model of monetizing internal innovation, shifting development costs to partners, and retaining upside via royalties.
- ▪Leerink Partners stated that the agreement with Roche reinforces its view that Zymeworks is building a repeatable, diversified business rather than relying on a single asset.
Story comments
Loading comments…